Joshua Reed Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Joshua Reed sold 3,053 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the transaction, the director owned 19,518 shares of the company’s stock, valued at approximately $1,048,897.32. This trade represents a 13.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

NASDAQ SRRK opened at $56.56 on Wednesday. The company has a current ratio of 8.64, a quick ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock Holding Corporation has a 12 month low of $27.07 and a 12 month high of $57.80. The stock has a market cap of $6.78 billion, a price-to-earnings ratio of -15.75 and a beta of 0.67. The company’s 50 day moving average is $48.79 and its two-hundred day moving average is $46.75.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same period last year, the company posted ($0.67) EPS. As a group, research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Institutional Trading of Scholar Rock

Several hedge funds have recently modified their holdings of SRRK. IFP Advisors Inc grew its holdings in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Scholar Rock during the fourth quarter valued at $30,000. Summit Securities Group LLC bought a new position in Scholar Rock during the fourth quarter valued at $31,000. EverSource Wealth Advisors LLC lifted its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares during the last quarter. Finally, Hilton Head Capital Partners LLC purchased a new position in shares of Scholar Rock in the 4th quarter worth $44,000. 91.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wedbush boosted their price objective on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. HC Wainwright upped their price target on Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Tuesday, April 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).